Get Started

REGN

NASD Regeneron Pharmaceuticals, Inc.
Oct 31, 2026 · 11:31 AM ET EOD Market Closed

$927.89 ↑ +0.00 (+0.00%) Trading Up from the previous close of $927.89, $7.46 below the day’s high of $935.35

YTD change
+20.21%
vs 20-day SMA
+19.07%
vs 200-day SMA
+25.96%

Price ranges

Previous day
$839.08 $935.35
open $869.43 close $927.89
+$58.46 (+6.72%)
Today
$839.08 $935.35
$927.89
Past week
$796.61 $828.19
from $819.09 now $927.89
+$108.80 (+13.28%)
Past month
$722.02 $828.19
from $734.81 now $927.89
+$193.08 (+26.28%)
This year
$591.52 $935.35
from $771.87 now $927.89
+$156.02 (+20.21%)

Price & Performance

+226.47 (+32.29%) / 6M

$574.48$701.01$827.54$954.07May 1Aug 3Oct 30

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 23.4% away from all-time highs of $1,211.20
  • REGN is up 20% since the beginning of the year
  • REGN is up 42% over the past 12 months
  • REGN is up 26% over the past 1 month
  • 2% of all REGN investors are betting against REGN

REGN reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +42.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $14.29
Earnings momentum +12.9% Quarterly EPS growth
Quarterly change +12.9%

Valuation

P/E ratio 20.10
Enterprise value $81.5B
Beta 0.09

Balance sheet & scale

Income$4.3M
Revenue$15.5B
Cash$8.0B
Debt$2.7M
Income / Debt 1.60×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $93.8B

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Competitor comparison

TickerCompany PriceChange
IQV IQVIA Holdings Inc $267.33 -2.81%
CRL Charles River Laboratories International, Inc. $359.41 -4.44%
ICLR ICON Plc $211.36 -1.91%
IT Gartner, Inc. $228.79 +1.66%
MDGL Madrigal Pharmaceuticals, Inc. $430.36 -0.31%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.